Trial Profile
An immunohistochemical study assessing factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to somatostatin analogues.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 May 2016
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary) ; Somatostatins
- Indications Acromegaly; Pituitary adenoma
- Focus Therapeutic Use
- 30 May 2016 New trial record